We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
- Authors
Draisma, Gerrit; Etzioni, Ruth; Tsodikov, Alex; Mariotto, Angela; Wever, Elisabeth; Gulati, Roman; Feuer, Eric; de Koning, Harry
- Abstract
The time by which prostate-specific antigen (PSA) screening advances prostate cancer diagnosis, called the lead time, has been reported by several studies, but results have varied widely, with mean lead times ranging from 3 to 12 years. A quantity that is closely linked with the lead time is the overdiagnosis frequency, which is the fraction of screen-detected cancers that would not have been diagnosed in the absence of screening. Reported overdiagnosis estimates have also been variable, ranging from 25% to greater than 80% of screen-detected cancers.
- Publication
Journal of the National Cancer Institute, 2009, Vol 101, Issue 6, p374
- ISSN
1460-2105
- Publication type
Journal Article
- DOI
10.1093/jnci/djp001